Cargando…
Two drugs are better than one. A short history of combined therapy of ovarian cancer
Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often t...
Autores principales: | Bukowska, Barbara, Gajek, Arkadiusz, Marczak, Agnieszka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709392/ https://www.ncbi.nlm.nih.gov/pubmed/26793017 http://dx.doi.org/10.5114/wo.2014.43975 |
Ejemplares similares
-
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
por: Gralewska, Patrycja, et al.
Publicado: (2020) -
Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer
por: Gajek, Arkadiusz, et al.
Publicado: (2021) -
Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
por: Gralewska, Patrycja, et al.
Publicado: (2021) -
Olaparib-Resistant BRCA2(MUT) Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
por: Biegała, Łukasz, et al.
Publicado: (2023) -
The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)